

Egyptian International Pharmaceutical Industries Company - EIPICO



Press release

EPICO achieves record business results in the first half of 2021.

Our total sales exceed 1.5 billion Egyptian pounds.

The volume of exports reaches about 23 million dollars, with a growth rate of 45%.

The growth of eye products sales in June and we account for 23% of the total number of sold packages.

Tenth of Ramadan on August 7, 2021

Dr. Ahmed Kelani, Chairman and Managing Director of the Egyptian International Pharmaceutical Industries "EIPICO" - the largest subsidiary of Acdima Pharmaceuticals Company, said that "EIPICO" achieved good business results during the first half of this year, which reflects great success towards restoring its worthy position as One of the largest pharmaceutical companies in Egypt, with total sales during the first half of 2021 exceeding 1.540 billion Egyptian pounds.

Despite the continuing impact of the Coronavirus epidemic during the first half of 2021, whether in Egypt or in all countries of the world, EIPICO was able to outdo itself and achieve many achievements.

Dr. Kelani stressed that EIPICO's major projects and strategic plans do not deter us at all from fulfilling our first commitment towards providing medicine to the Egyptian citizen in accordance with the best international standards and at competitive prices.

This comes in addition to the EIPICO company maintaining its outstanding performance in the field of drug export during the first half of this year, as it achieved a growth of 45% over the same period in 2020, with total exports of about \$22.7 million, ranking alone at the top of the drug exporting companies in the world. Egypt accounts for about 23% of the total Egyptian pharmaceutical exports, pointing to the expansion of "EIPICO" in the Latin American markets, as it succeeded in exporting to Venezuela, bringing the number of countries it exports to 70 countries spread all over the world.

On the other hand, Dr. Ahmed Kelani explained that EIPICO eye products receive special attention because they require the provision of production areas of a special technological nature and more than strict quality standards. EIPICO is unique in owning many production areas for the production of eye products "drops and ointments." Either in Factory No. 1, or Factory No. 2.

Dr. Kelani said that "EPICO" topped the list of companies selling eye products in Egypt during the month of June, in terms of the number of packages, acquiring 23% of the total number of eye products packages sold in the market, achieving a growth of 9.1%, while the market achieved Packaging of eye products grew by 0.3% over the same month last year.

He pointed out that "EIPICO" also owns three products among the top 10 selling eye products in terms of the number of packages, and they are "Dexatrol" product, which is the best-selling product in the eye products market in Egypt, "Tobrin" product and "Nostamin" product.



Egyptian International Pharmaceutical Industries Company - EIPICO



Press release

Kelani praised the performance of all the company's approximately 5,000 workers in various sectors, departments, and branches in all parts of Egypt and abroad, stressing that this success would not have been achieved without the strong harmony between them and the teamwork spirit, directing their thanks and appreciation for this outstanding performance.

About the Egyptian International Company for Pharmaceutical Industries - EPICO

EIPICO was established in the 10th of Ramadan City in 1980 with a capital of 7 million Egyptian pounds, which has now been increased to 1500 million pounds, as an Egyptian joint stock company operating in accordance with the investment law and has been listed on the Egyptian Stock Exchange since 1995 under the code (PHAR.CA). EIPICO started production in 1985 as a leading company in the pharmaceutical industry in Egypt according to the rules of good manufacturing practices.

EIPICO has two factories built on an area of 120,000 square meters, with 9 sterile areas being the largest and most advanced in Egypt and the Middle East and North Africa region and the first center for biotechnology and genetic engineering research for the manufacture of biological preparations.

EIPICO manufactures more than 400 pharmaceutical products covering 25 therapeutic groups .EIPICO ranks first in the Egyptian ophthalmology market by units. It is also the leading Egyptian pharmaceutical export company, as its products are exported to more than 69 countries around the world with a market share of 23% Total Egyptian pharmaceutical exports

For more information, please visit our official website https://eipico.com.eg

To communicate:

Investor Relations

Tenth of Ramadan - First Industrial Zone - B1

Tel: 055499199

Fax: 055499306

a.elmoraly@eipico.net

###